 |
|
|
 |
|
Assessment of Bone Growth Stimulator Is Mixed
|
 |  |  |  | Related Healthscout Videos |  |
|
Page: << Prev | 1 | 2 | 3 Cammisa also pointed out that the study did not find shorter lengths of stay for procedures with BMP and did not look at outpatient complications, which he said might be increased.
"I think [this study] serves as an impetus for surgeons to look for less expensive, but efficacious, bone growth factors other than BMP," he said. Also, Cammisa said, he'd like to see specific guidelines developed for the use of BMP.
Burton, who said the study "highlights the trend that many of us would have guessed, that the use of BMP is skyrocketing," added that more recent data might show something different.
Text Continues Below

If the study looked at data from 2007, he said, he believes the rates of anterior cervical complications would be reduced because many surgeons aren't using BMP for fusions in that area or are using smaller doses of the biological agent.
The surgeons agreed that more research is needed to determine who is an ideal candidate for BMP use and to assess the costs and benefits of the therapy.
More information
The U.S. National Library of Medicine has more on spinal fusion surgery.
Page: << Prev | 1 | 2 | 3
|
Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 6/30/2009
|
 |

SOURCES: Kevin Cahill, M.D., Ph.D., M.P.H., neurosurgeon, Brigham and Women's Hospital, Boston; Frank Cammisa Jr., M.D., chief, spinal surgical service, Hospital for Special Surgery, and associate professor, clinical surgery, Weill Cornell Medical College, New York City; Richard Fessler, M.D., chief of surgery and neurosurgeon, St. John Hospital and Medical Center, Detroit; Douglas Burton, M.D., orthopedic surgeon and professor, orthopedic surgery, University of Kansas Hospital and School of Medicine, Kansas City, Kan.; July 1, 2009, Journal of the American Medical Association
|